Catabasis Pharma (CATB) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Oppenheimer Maintains Bullish View on Catabasis (CATB)
November 13, 2017 12:38 PM ESTOppenheimer analyst Hartaj Singh reiterated an Outperform rating and $7 price target on Catabasis (NASDAQ: CATB).
Singh notes positive MoveDMD data continues to strengthen.
For an analyst ratings summary and ratings history on Catabasis click here. For more ratings news on Catabasis click here.
Shares of Catabasis closed at $1.82 yesterday.
... More